Intellia Presents Positive Results from the Phase 2 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE)
24 oct. 2024 08h01 HE
|
Intellia Therapeutics, Inc.
Deep attack rate reductions achieved in both dose levels tested; a single 50 mg dose resulted in a mean monthly attack rate reduction of 77% and 81% compared to placebo during weeks 1-16 and 5-16,...
Intellia Therapeutics Announces Initiation of HAELO Phase 3 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE)
07 oct. 2024 07h30 HE
|
Intellia Therapeutics, Inc.
NTLA-2002 is a single-dose treatment designed to prevent potentially life-threatening swelling attacks in people with hereditary angioedema (HAE)NTLA-2002 is Intellia’s second in vivo candidate to...
Intellia Therapeutics to Present Data from the Phase 2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the 2024 ACAAI Annual Scientific Meeting
12 sept. 2024 07h30 HE
|
Intellia Therapeutics, Inc.
First presentation of detailed Phase 2 results following previous positive topline announcement that study of NTLA-2002 met primary and all secondary endpoints Intellia to host investor webcast on...
Intellia Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for NTLA-2002, an In Vivo CRISPR-Based Investigational Therapy for the Treatment of Hereditary Angioedema (HAE)
02 mars 2023 07h00 HE
|
Intellia Therapeutics, Inc.
CAMBRIDGE, Mass., March 02, 2023 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapies...
Intellia Therapeutics Announces Positive Interim Clinical Data for its Second Systemically Delivered Investigational CRISPR Candidate, NTLA-2002 for the Treatment of Hereditary Angioedema (HAE)
16 sept. 2022 07h00 HE
|
Intellia Therapeutics, Inc.
Positive interim clinical data further validate the modularity of Intellia’s industry-leading genome editing platform and its potential to target a multitude of genetic diseases A single dose of...
Hereditary Angioedema Treatment Market Report Up to 2031: Visiongain Research Inc
20 déc. 2021 10h16 HE
|
Visiongain Ltd
Visiongain has published a new report on Hereditary Angioedema Treatment Market Report 2021-2031: Forecasts By Drug Class (C1-esterase Inhibitor, Bradykinin B2 Receptor Antagonist, Kallikrein...
Geriatric Medicines Market Report Up to 2031: Visiongain Research Inc
20 déc. 2021 10h14 HE
|
Visiongain Ltd
Visiongain has published a new report on Geriatric Medicines Market Report 2021-2031: Forecasts By Therapeutic Category (Analgesic, Antihypertensive, Statins, Antidiabetic, Proton Pump Inhibitor,...
Intellia Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of NTLA-2002 for the Treatment of Hereditary Angioedema
13 déc. 2021 07h30 HE
|
Intellia Therapeutics, Inc.
CAMBRIDGE, Mass., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics using...
Shire plc: CHMP Recommends EU Marketing Authorisation of lanadelumab for the Prevention of HAE Attacks
19 oct. 2018 08h00 HE
|
Shire plc
CHMP Recommends EU Marketing Authorisation of lanadelumab for the Prevention of HAE Attacks - If approved, lanadelumab would be the first monoclonal antibody for the preventive treatment of...